Search Results for

PathGroup Announces Partnership with digiChart

Includes New Enhanced Lab Interface Exclusively for PathGroup and digiChart Clients

BRENTWOOD, TENN. – (April 8, 2016) – PathGroup, one of the largest private providers of pathology services in the United States, announced today a unique partnership with digiChart, one of the largest specialty-focused EHR providers in the women’s health space.

PathGroup and digiChart have partnered to develop a new ordering interface that will give the digiChart EHR product full bi-directional lab interface capabilities. PathGroup and digiChart clients will be able to both place orders and receive results through their existing digiChart EHR, creating a seamless process that will both save time in the office and simplify the lab ordering workflow for their practice. “PathGroup is committed to providing our clients with superior service. We have always been a leader in utilizing technology to deliver fast, accurate results and this partnership with digiChart adds ease of ordering for our mutual clients to that equation,” stated Dan Valenti, Senior Vice President and Chief Information Officer at PathGroup.

“As one of the largest providers of women’s health services in the United States, PathGroup wanted an EHR partner that showed that same commitment to women’s health providers. We felt that by working together, PathGroup and digiChart could significantly enhance and simplify the workflow for our mutual clients, helping them ultimately better serve their patients,” stated Richard Halstead, Executive Vice President and Chief Commercial Officer at PathGroup.

Built by OB/GYNs for OB/GYNs, digiChart’s specialty-focused EHR mimics the workflow in the OB/GYN practice, improves clinical decision-making, and provides unique functionality to enhance patient care. “This partnership with PathGroup significantly enhances our lab interface capabilities, allowing our clients’ offices to quickly and easily order and receive results for all their lab testing needs, directly in their digiChart EHR,” stated Rodney Hamilton, M.D., Chief Executive Officer at digiChart. digiChart also provides revenue cycle management tools that integrate seamlessly with the EHR, providing faster, more accurate processing of claims.

PathGroup and digiChart look forward to further enhancing the partnership with future collaborations, focused on ensuring clients have services that benefit both their practice and their patients.

About PathGroup

Founded in 1965, PathGroup has evolved into a premier provider of anatomic, clinical and molecular pathology services, as well as one of the largest providers of Women’s Health services in the United States. Privately held and physician centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships.  PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results.  The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers and most importantly, patients. One Lab; Total Service.  For more information, visit www.pathgroup.com.

About digiChart

digiChart offers specialized tools, services, and education to help OB/GYN practices compete with the larger practices or hospitals seeking to control more of the care continuum.  Our tools deliver value clinically, operationally, and financially providing insight to know how to make the right changes to keep your practice on course. digiChart has expanded its offering to enhance the foundational EHR with new medical billing services and practice analytics to give OB/GYN practices the resources needed to succeed. Improving the Practice of Women’s Health. For more information, visit digiChart.com.

Contact:

Brent Sower
AVP Marketing
PathGroup
615.234.3908
bsower@pathgroup.com

Kathy Gill
VP Marketing and Communications
digiChart, Inc.
615.481.6646
kgill@digichart.com

New Test Announcement – Informed Pregnancy Screen

Effective March 1, 2016, PathGroup will offer Informed Pregnancy Screen, a non-invasive prenatal screen (NIPS) that analyzes cell-free DNA (cfDNA) using next-generation sequencing to determine if a pregnancy is at increased risk for certain chromosome aneuploidies. Informed Pregnancy Screen has an industry-leading ‘no-call’ rate of 0.1% and a personalized positive predictive value (PPV) is included on every positive result. The test can be performed as early as 10 weeks gestation and results will be available in approximately 1 week. Electronic ordering and results delivery is available to PathGroup clients and post-test genetic counseling is available to patients if desired.

Click Here to read more.

Urinalysis Testing and Reporting – Update

This change will take effect on February 15, 2016

Effective February 15, 2016, PathGroup will be implementing the following procedure for all Urinalysis testing in an effort to improve the turnaround times as well as to better manage healthcare costs.

Click Here to read more.

ARUP – Test Update

January 4, 2016

PathGroup has been notified by our reference laboratory partner, ARUP Laboratories, of a resulting issue affecting specific send out testing that was processed through their facility. A compliance statement on results released from August 14, 2014 through November 13, 2015 was omitted while performing an interface coding change to the following tests:

  • Giardia lamblia Antibodies by ELISA (GLABS)
  • Glutathione, Total (GLUTH)
  • Vitamin B5 (B5A)

The omission of the compliance statement did not affect the test result and all test results remain unchanged.

Click Here to read more.

FibroMeter – Test Update

January 4, 2016

PathGroup has been notified by our reference laboratory partner, ARUP Laboratories, that an incorrect unit of measure for Blood Urea Nitrogen (BUN) was reported using U/L instead of the correct unit of measure, mg/dL. BUN is a component of the FibroMeter assay (FIBROM) which ARUP Laboratories performs. Results were not affected by the associated incorrect unit of measure and all scores, classifications, and overall test result interpretations remain unchanged.

Click Here to read more.

CPT Code Changes – Update

This change will take effect on January 1, 2016

Effective January 1, 2016, the American Medical Association (AMA) will introduce numerous changes to current procedural terminology (CPT) codes that include 11 deleted codes, 28 new codes and 50 revised codes. To ensure you are properly reimbursed for laboratory services rendered, PathGroup recommends you implement these changes (along with any other applicable CPT code changes) into your practice’s billing and coding structure by January 1, 2016.

Click Here to read more.

CPT Code Changes – New Obstetrics Panel Update

This change will take effect on January 1, 2016

Effective January 1, 2016, the American Medical Association (AMA) will introduce numerous changes to current procedural terminology (CPT) codes that include 11 deleted codes, 28 new codes and 50 revised codes. As a result, a new Obstetrics panel that includes HIV testing will be added and will require the use of CPT code 80081. In order to bill this code all components of the panel must be performed. The added service for this new panel includes HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result (87389).

Click Here to read more.

PAI1 4G/5G – Test Update

This change will take effect December 15, 2015

Overview and Clinical Utility:

Effective December 15, 2015, the gene name Plasminogen Activator Inhibitor, Type 1 (PAI1) will change to Serpin Peptidase Inhibitor, Clade E, Member 1 (SERPINE1). The orderable test code, PAI, will not change, however PathGroup will update all applications and directories to reflect the revised test name and description outlined below. In addition, PathGroup will implement new test methodology by PCR followed by fragment length analysis.

Click Here to read more.

Trichomonas – Test Update

This change will take effect December 7, 2015

Overview and Clinical Utility:

Effective December 7, 2015 PathGroup Labs will no longer be performing wet mount testing or culture for Trichomonas vaginalis In order to provide our clients with the most up to date infectious disease testing methods. According to the 2015 Sexually Transmitted Diseases Treatment Guidelines recently published by the CDC, culture is no longer considered the gold standard method for diagnosing T. vaginalis infection with the advent of molecular detection methods.  Wet mount microscopic analysis suffers from extremely low sensitivity which can give rise to a high number of false negative results. PathGroup will continue to offer testing for Trichomonas vaginalis by the APTIMA assay.

Click Here to read more.

Hendersonville Patient Service Center

This change will take effect November 1, 2015

Effective November 1, 2015, PathGroup’s Patient Service Center located on New Shackle Island Road in Hendersonville will no longer accept patients. If you have laboratory specimens for PathGroup and are not on a regular courier schedule, please call Client Services at 888-474-5227 to arrange a special pickup after November 1, 2015.

Click Here to read more.